The Synergistic Effect of PARP Inhibitors and Irinotecan in Small Cell Lung Cancer Cells [0.03%]
PARP抑制剂和伊立替康在小细胞肺癌细胞中的协同作用
Songji Oh,Soyeon Kim,Bhumsuk Keam et al.
Songji Oh et al.
Purpose: This study focused on combining irinotecan with Poly (ADP-ribose) polymerase (PARP) inhibitors to explore the potential for novel combination therapeutics in small cell lung cancer (SCLC). ...
Single-Cell Heterogeneity of EGFR Pathway Is Linked to Unique Signatures of Drug Response and Malignancy in Patient Derived Glioblastoma Stem Cells [0.03%]
基于患者的胶质母细胞瘤干细胞中的EGFR通路单细胞异质性与药物反应及恶性程度的独特特征相关
Michael D Masterman-Smith,Nicholas A Graham,Eduard H Panosyan et al.
Michael D Masterman-Smith et al.
Purpose: In glioblastoma, the therapeutically intractable and resistant phenotypes can be derived from glioma stem cells, which often have different underlying mechanisms from non-stem glioma cells. Aberrant signaling acr...
Long-Term Survival Outcomes of Surgical Resection for Lung Adenocarcinoma with Intraoperatively Diagnosed Pleural Metastasis: Target Treatment Era [0.03%]
术中诊断胸膜转移的肺腺癌手术切除长期生存结局及靶向治疗时代的影响
Yelee Kwon,Jae Kwang Yun,Geun Dong Lee et al.
Yelee Kwon et al.
Purpose: This study aimed to evaluate the clinical impact of main tumor resection on long-term survival compared with pleural biopsy alone in patients with lung adenocarcinoma who were intraoperatively diagnosed with pleu...
Outcomes of Stereotactic Body Radiation Therapy for Large Uveal Melanoma: A Retrospective Analysis of Asian Population [0.03%]
立体放射治疗大型脉络膜黑色素瘤的疗效分析：一项亚洲人种回顾性研究
Jong Won Park,Seowoong Jun,Ki Chang Keum et al.
Jong Won Park et al.
Purpose: To investigate the clinical outcomes of stereotactic body radiation therapy (SBRT) in patients with large uveal melanoma (UM). Materials and meth...
Prognostic Performance of the Next-Generation Sequencing-Based Multigene Assay in Early Breast Cancer Patients Treated According to the 21-Gene Assay Results [0.03%]
新一代测序多基因检测在指导早期乳腺癌患者治疗中的预后性能研究
Eunhye Kang,Jong-Ho Cheun,Jeeyeon Lee et al.
Eunhye Kang et al.
Purpose: Multigene assays guide treatment decisions in early-stage hormone receptor-positive breast cancer. OncoFREE, a next-generation sequencing assay using 179 genes, was developed for this purpose. This study aimed to...
Clinical Impact of TP53 Mutations in Patients with Head and Neck Cancer Who Were Treated with Targeted Therapies or Immunotherapy [0.03%]
TP53突变在头颈部肿瘤靶向治疗或免疫治疗患者中的临床影响
Eun Joo Kang,Shinwon Hwang,Yun-Gyoo Lee et al.
Eun Joo Kang et al.
Purpose: TP53 mutations are common in head and neck squamous cell carcinoma (HNSCC). We evaluated their clinical impact in patients treated with targeted agents or immunotherapy in the KCSG HN15-16 TRIUMPH trial. ...
Real-World Effectiveness and Safety of Intravenous Daratumumab in Patients with Multiple Myeloma: A Multicenter, Observational Study from Korea [0.03%]
达雷木单抗静脉给药在多发性骨髓瘤患者中的疗效和安全性：一项韩国多中心观察研究
Youngil Koh,Sung-Soo Yoon,Kihyun Kim et al.
Youngil Koh et al.
Purpose: Daratumumab is a novel, first-in-class monoclonal antibody approved for use as monotherapy and in combination with other treatments for patients with multiple myeloma (MM). The aim of this observational study was...
Unraveling the Genetic Landscape of Langerhans Cell Histiocytosis in Korean Patients: Comprehensive Insights from Mutational Profiles and Clinical Correlations [0.03%]
解码朗格汉斯细胞组织细胞增生症的遗传图谱：韩国患者突变特征与临床表型的综合分析
Kyung-Nam Koh,Ha Ra Jun,Ji-Young Lee et al.
Kyung-Nam Koh et al.
Purpose: This study aimed to conduct a comprehensive genetic analysis of patients with Langerhans cell histiocytosis (LCH), focusing on the frequency of MAPK pathway mutations, detailed mutation profiles of MAPK pathway g...
CYBC1 Drives Glioblastoma Progression via ROS and NF-κB Pathways [0.03%]
CYBC1通过ROS和NF-κB途径驱动胶质母细胞瘤进展
Hyeon Ji Kim,Tae-Jun Kim,Jin-Hwa Cho et al.
Hyeon Ji Kim et al.
Purpose: This study aims to investigate the role of Cytochrome b-245 chaperone 1 (CYBC1) in glioblastoma (GBM) progression, focusing on its involvement in reactive oxygen species (ROS) production and associated signaling ...
A Prospective, Single-Cohort, Open, Multi-Center, Observational Study of Sublingual Fentanyl for Breakthrough Cancer Pain: Effectiveness, Safety, and Tolerability in Korean Cancer Patients [0.03%]
一项前瞻性、单组、开放性、多中心的舌下含服芬太尼癌痛爆发痛治疗疗效、安全和耐受性韩国患者观察研究
Youn Seon Choi,Su-Jin Koh,Woo Kyun Bae et al.
Youn Seon Choi et al.
Purpose: Fentanyl, a highly lipophilic opioid, was developed as a sublingual fentanyl tablet (SFT) for the management of breakthrough cancer pain (BTcP), and its efficacy and safety were confirmed in a randomized, control...